<div id="readability-page-1"><div><p>SBP GROUP (01177.HK)<span> </span><span> -0.050 (-0.885%)  </span> <span> Short selling $43.14M; Ratio 14.151%  </span>  announced that preclinical research data of its innovative drug TQF6422, an &#34;ActRII A/B monoclonal antibody&#34; independently developed by its subsidiary Chia Tai Tianqing, were presented at the 2026 European Congress on Obesity (ECO).</p><p>TQF6422 is a fully human monoclonal antibody targeting ActRII A/B. By specifically binding to ActRII A/B receptors and blocking ligand (Activin, Myostatin)-mediated signal transduction, it promotes skeletal muscle growth while enhancing lipolysis, thereby achieving dual effects of fat reduction and muscle gain.</p><p>The in vitro activity of TQF6422 is more than 10 times higher than that of comparable products. In combination therapy with semaglutide, TQF6422 demonstrated significant synergistic effects. In an obese monkey model, compared with semaglutide monotherapy, the combination regimen increased fat reduction by 1.5 times to 2 times, improved lean mass retention by 72% to 85%, and fat reduction accounted for 93% of total weight loss. (jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.)</p></div></div>

159929

588130

<p>SBP GROUPannounced preclinical data for its innovative drug TQF6422 at the 2026 European Congress on Obesity. TQF6422, a fully human monoclonal antibody targeting ActRII A/B, promotes muscle growth and fat reduction. Its in vitro activity exceeds comparable products by over 10 times. In combination with semaglutide, TQF6422 showed significant synergistic effects, increasing fat reduction by 1.5 to 2 times in an obese monkey model, with fat loss comprising 93% of total weight loss.</p>

AASTOCKS News

China Universal 800 Health Care ETF

SPDR S&P Biotech

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Ark Genomic Revolution ETF

Penghua SSE STAR Biology and Medicine ETF

Proshares UltraShort Nasdaq Biotech

Tianhong CNI BIOMEDICINE ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

ALPS Medical Breakthrough

China Southern Hang Seng Biotech ETF(QDII)

Direxion S&P Biotech Bull 3X

Huaan Hang Seng Biotech ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Guotai SSE STAR Brand Name Drug ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

SBP GROUP

SBP GROUP  Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity